EUR 0.02
(-4.17%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 40.56 Million EUR | 14.76% |
2022 | 37.05 Million EUR | -2.53% |
2021 | 38.01 Million EUR | 10491.9% |
2020 | 358.94 Thousand EUR | -66.29% |
2019 | 1.06 Million EUR | 86.57% |
2018 | 570.75 Thousand EUR | -5.5% |
2017 | 604 Thousand EUR | -64.12% |
2016 | 1.68 Million EUR | 41978.93% |
2015 | 4000.00 EUR | -20.0% |
2014 | 5000.00 EUR | -28.57% |
2013 | 7000.00 EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2023 Q2 | 21.79 Million EUR | 20.67% |
2023 FY | 42.52 Million EUR | 14.76% |
2023 Q4 | 20.72 Million EUR | -4.9% |
2022 Q4 | 18.06 Million EUR | -4.89% |
2022 FY | 37.05 Million EUR | -2.53% |
2022 Q2 | 18.99 Million EUR | 4576285.54% |
2021 FY | 38.01 Million EUR | 10491.9% |
2021 Q4 | 415.00 EUR | 0.0% |
2021 Q2 | - EUR | -100.0% |
2020 Q2 | 16 Thousand EUR | -92.23% |
2020 FY | 358.94 Thousand EUR | -66.29% |
2020 Q4 | 342.94 Thousand EUR | 2043.4% |
2019 Q4 | 205.84 Thousand EUR | -76.04% |
2019 FY | 1.06 Million EUR | 86.57% |
2019 Q2 | 859 Thousand EUR | 362.45% |
2018 Q4 | 185.75 Thousand EUR | -51.75% |
2018 FY | 570.75 Thousand EUR | -5.5% |
2018 Q2 | 385 Thousand EUR | 26.64% |
2017 Q2 | 300 Thousand EUR | -78.33% |
2017 Q4 | 304 Thousand EUR | 1.33% |
2017 FY | 604 Thousand EUR | -64.12% |
2016 Q2 | 298 Thousand EUR | 29700.0% |
2016 FY | 1.68 Million EUR | 41978.93% |
2016 Q4 | 1.38 Million EUR | 364.61% |
2015 Q2 | 3000.00 EUR | 0.0% |
2015 Q4 | 1000.00 EUR | -66.67% |
2015 FY | 4000.00 EUR | -20.0% |
2014 FY | 5000.00 EUR | -28.57% |
2013 FY | 7000.00 EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Nicox S.A. | 257 Thousand EUR | -15683.658% |
FERMENTALG | 4.05 Million EUR | -899.852% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -2959.125% |